FDA grants approval for bluebird’s Zynteglo to treat beta-thalassemia
Pharmaceutical Technology
AUGUST 18, 2022
A custom-made, one-dose gene therapy, Zynteglo is indicated for such patients who need red blood cells (RBCs) transfusions on a regular basis. 0 genotypes. A genetic blood ailment, beta-thalassemia is caused by beta-globin gene mutations and results in a substantial decline or lack of production of adult haemoglobin.
Let's personalize your content